Review



◦c with anti dpp4  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc ◦c with anti dpp4
    ◦C With Anti Dpp4, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 54 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pm41765309-68-6-11
    Average 94 stars, based on 54 article reviews
    ◦c with anti dpp4 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Western Blot:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: .. Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63.

    Article Title:
    Article Snippet: .. Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher

    Blocking Assay:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: .. Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63.

    Article Title:
    Article Snippet: .. Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher

    Immunofluorescence:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63. ..

    Article Title:
    Article Snippet: Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher ..

    Imaging:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63. ..

    Staining:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63. ..

    Marker:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63. ..

    Infection:

    Article Title: Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
    Article Snippet: Antibodies used for western blotting Primary Antibody Antibody species Blocking buffer Dilution Catalog number DPP4/CD26 Rabbit 5% BSA/TBST 1:1000 Cell Signaling Technology 67138S ACE2 Rabbit 5% milk/TBST 1:1000 Cell Signaling Technology 4355S MUC5AC Mouse 5% milk/TBST 1:500 Sigma-Aldrich AMAB91539 Type IV btubulin Rabbit 5% milk/TBST 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 5% milk/TBST 1:2000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 5% milk/TBST 1:2000 Sino Biological 40641-T62 GAPDH Rabbit 5% milk/TBST 1:2000 Cell Signaling Technology 2118S Secondary Antibody Antibody species Blocking buffer Dilution Catalog number Anti-rabbit IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7074S Anti-mouse IgG HRP-linked Goat Same as primary 1:3000 Cell Signaling Technology 7076S Table S2. .. Antibodies used for immunofluorescence assay Primary Antibody Antibody species Dilution Catalog number DPP4/CD26 Rabbit 1:1000 Cell Signaling Technology 67138S MUC5AC Mouse 1:1000 Sigma-Aldrich AMAB91539 Type IV b-tubulin Rabbit 1:1000 Abcam ab179509 SARS-CoV-2 Nucleocapsid Rabbit 1:1000 Genetex GTX135357 MERS-CoV Nucleocapsid Mouse 1:1000 Sino Biological 40068-MM10 HCoV-NL63 Nucleocapsid Rabbit 1:1000 Sino Biological 40641-T62 Secondary Antibody Species Dilution Catalog number Alexa Fluor secondary dyes Donkey 1:1000 Thermo Fisher Figure S1 Immunofluorescence imaging controls in uninfected cultures. (A) Uninfected nasal ALI cultures were stained with ciliated cell marker type IV b-tubulin (green), goblet cell marker mucin MUC5AC (red), and Hoescht (blue) to illustrate typical morphology prior to infection. (B) Uninfected cultures were stained with primary antibodies against the nucleocapsid protein for each of SARS-CoV-2, MERS-CoV, and HCoV-NL63. ..



    Similar Products

    ◦c with anti dpp4  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc ◦c with anti dpp4
    ◦C With Anti Dpp4, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pm41765309-68-6-11
    Average 94 stars, based on 1 article reviews
    ◦c with anti dpp4 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cd26  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc cd26
    Scoring of <t>CD26</t> immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.
    Cd26, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pmc12711487-79-7-10
    Average 94 stars, based on 1 article reviews
    cd26 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    dpp4 cd26  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc dpp4 cd26
    Scoring of <t>CD26</t> immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.
    Dpp4 Cd26, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pmc12709056-57-12-14
    Average 94 stars, based on 1 article reviews
    dpp4 cd26 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti cd26 rabbit mab  (Proteintech)
    94
    Proteintech anti cd26 rabbit mab
    Scoring of <t>CD26</t> immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.
    Anti Cd26 Rabbit Mab, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Antibody/pmc12381242__41467_2025_62731_MOESM5_ESM-25-185-188
    Average 94 stars, based on 1 article reviews
    anti cd26 rabbit mab - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti dpp4  (OriGene)
    93
    OriGene anti dpp4
    Scoring of <t>CD26</t> immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.
    Anti Dpp4, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/CD26+(DPP4)+Rabbit+Polyclonal+Antibody/10__1158_slash_0008___5472__can___24___4323-88-83-100
    Average 93 stars, based on 1 article reviews
    anti dpp4 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    immunoblots cd26  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc immunoblots cd26
    a Under normal conditions, (1) terminally differentiated cardiomyocytes have condensed inaccessible chromatin that we hypothesise becomes (2) more accessible by tumour secreted factors, promoting loss of cardiomyocyte maturity and (3) intercalation of DNA damaging chemotherapeutics into now accessible chromatin resulting in DNA breaks and cardiotoxicity (BioRender Lorenzana (2025) https:// BioRender.com/2dyaqis). b Graph shows baseline cumulative inosine and hypoxanthine plasma levels in breast cancer patients from the MANTICORE trial placebo arm. Patients are grouped above or below a threshold of 6 μM: no cardiotoxicity (teal), mild cardiotoxicity (lilac) and moderate cardiotoxicity (purple), n = 22 patients, * P = 0.036 comparing CIC and no CIC above and below a post-hoc analysis determined threshold of 6 μM in a 2 × 2 contingency table, P -value is based on Fisher’s exact two-sided test. c Extracellular purinergic signalling and synthesis of inosine and hypoxanthine (BioRender) . d <t>Immunoblots</t> show <t>CD26,</t> ADA, PNP, CLATHRIN in isolated endosomes in parental and ZNF281 KO A549 cells, n = 3 biological replicates, * P = 0.05 compared to parental endosomes. EEA1 used as a loading control. e Immunoblots show CD26, ADA, PNP in membrane cell fractionation of parental and ZNF281 KO A549 cells, n = 4 biological replicates, * P = 0.0143 compared to parental membrane fraction. EGFR was as a loading control. f Inosine and hypoxanthine measured in cell supernatant, n = 3 biological replicates, * P = 0.05 compared to parental supernatant. g Immunoblots show ZNF281 in control and ZNF281 overexpressing (OE) mouse liver ( n = 4), colon ( n = 3, control and n = 4, ZNF281 OE), ileum ( n = 3, control and n = 4, ZNF281 OE) and stomach ( n = 3) mice, * P = 0.0143, 0.0286, 0.0286, 0.05 respectively compared to control tissue. ACTIN used as a loading control. h Immunoblots show CD26, ADA, PNP in isolated membrane fractions from control and ZNF281 OE liver n = 4 and ileum n = 3 mice, * P = 0.0143 and * P = 0.05 compared to control tissue. EGFR was used as a loading control. i Mouse serum inosine and hypoxanthine in control vs. ZNF281 OE mice, n = 3 control and n = 5 ZNF281 OE mice, * P = 0.0357 compared to control mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values based on one-sided Mann-Whitney Test. Source Data file is provided.
    Immunoblots Cd26, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pmc12297588-242-7-9
    Average 94 stars, based on 1 article reviews
    immunoblots cd26 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti dpp4  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti dpp4
    a Under normal conditions, (1) terminally differentiated cardiomyocytes have condensed inaccessible chromatin that we hypothesise becomes (2) more accessible by tumour secreted factors, promoting loss of cardiomyocyte maturity and (3) intercalation of DNA damaging chemotherapeutics into now accessible chromatin resulting in DNA breaks and cardiotoxicity (BioRender Lorenzana (2025) https:// BioRender.com/2dyaqis). b Graph shows baseline cumulative inosine and hypoxanthine plasma levels in breast cancer patients from the MANTICORE trial placebo arm. Patients are grouped above or below a threshold of 6 μM: no cardiotoxicity (teal), mild cardiotoxicity (lilac) and moderate cardiotoxicity (purple), n = 22 patients, * P = 0.036 comparing CIC and no CIC above and below a post-hoc analysis determined threshold of 6 μM in a 2 × 2 contingency table, P -value is based on Fisher’s exact two-sided test. c Extracellular purinergic signalling and synthesis of inosine and hypoxanthine (BioRender) . d <t>Immunoblots</t> show <t>CD26,</t> ADA, PNP, CLATHRIN in isolated endosomes in parental and ZNF281 KO A549 cells, n = 3 biological replicates, * P = 0.05 compared to parental endosomes. EEA1 used as a loading control. e Immunoblots show CD26, ADA, PNP in membrane cell fractionation of parental and ZNF281 KO A549 cells, n = 4 biological replicates, * P = 0.0143 compared to parental membrane fraction. EGFR was as a loading control. f Inosine and hypoxanthine measured in cell supernatant, n = 3 biological replicates, * P = 0.05 compared to parental supernatant. g Immunoblots show ZNF281 in control and ZNF281 overexpressing (OE) mouse liver ( n = 4), colon ( n = 3, control and n = 4, ZNF281 OE), ileum ( n = 3, control and n = 4, ZNF281 OE) and stomach ( n = 3) mice, * P = 0.0143, 0.0286, 0.0286, 0.05 respectively compared to control tissue. ACTIN used as a loading control. h Immunoblots show CD26, ADA, PNP in isolated membrane fractions from control and ZNF281 OE liver n = 4 and ileum n = 3 mice, * P = 0.0143 and * P = 0.05 compared to control tissue. EGFR was used as a loading control. i Mouse serum inosine and hypoxanthine in control vs. ZNF281 OE mice, n = 3 control and n = 5 ZNF281 OE mice, * P = 0.0357 compared to control mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values based on one-sided Mann-Whitney Test. Source Data file is provided.
    Anti Dpp4, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pmc12289001-254-23-24
    Average 94 stars, based on 1 article reviews
    anti dpp4 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    67138s ace2 rabbit  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc 67138s ace2 rabbit
    a Under normal conditions, (1) terminally differentiated cardiomyocytes have condensed inaccessible chromatin that we hypothesise becomes (2) more accessible by tumour secreted factors, promoting loss of cardiomyocyte maturity and (3) intercalation of DNA damaging chemotherapeutics into now accessible chromatin resulting in DNA breaks and cardiotoxicity (BioRender Lorenzana (2025) https:// BioRender.com/2dyaqis). b Graph shows baseline cumulative inosine and hypoxanthine plasma levels in breast cancer patients from the MANTICORE trial placebo arm. Patients are grouped above or below a threshold of 6 μM: no cardiotoxicity (teal), mild cardiotoxicity (lilac) and moderate cardiotoxicity (purple), n = 22 patients, * P = 0.036 comparing CIC and no CIC above and below a post-hoc analysis determined threshold of 6 μM in a 2 × 2 contingency table, P -value is based on Fisher’s exact two-sided test. c Extracellular purinergic signalling and synthesis of inosine and hypoxanthine (BioRender) . d <t>Immunoblots</t> show <t>CD26,</t> ADA, PNP, CLATHRIN in isolated endosomes in parental and ZNF281 KO A549 cells, n = 3 biological replicates, * P = 0.05 compared to parental endosomes. EEA1 used as a loading control. e Immunoblots show CD26, ADA, PNP in membrane cell fractionation of parental and ZNF281 KO A549 cells, n = 4 biological replicates, * P = 0.0143 compared to parental membrane fraction. EGFR was as a loading control. f Inosine and hypoxanthine measured in cell supernatant, n = 3 biological replicates, * P = 0.05 compared to parental supernatant. g Immunoblots show ZNF281 in control and ZNF281 overexpressing (OE) mouse liver ( n = 4), colon ( n = 3, control and n = 4, ZNF281 OE), ileum ( n = 3, control and n = 4, ZNF281 OE) and stomach ( n = 3) mice, * P = 0.0143, 0.0286, 0.0286, 0.05 respectively compared to control tissue. ACTIN used as a loading control. h Immunoblots show CD26, ADA, PNP in isolated membrane fractions from control and ZNF281 OE liver n = 4 and ileum n = 3 mice, * P = 0.0143 and * P = 0.05 compared to control tissue. EGFR was used as a loading control. i Mouse serum inosine and hypoxanthine in control vs. ZNF281 OE mice, n = 3 control and n = 5 ZNF281 OE mice, * P = 0.0357 compared to control mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values based on one-sided Mann-Whitney Test. Source Data file is provided.
    67138s Ace2 Rabbit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pmc10104492__pnas__2218083120__sapp-62-22-19
    Average 94 stars, based on 1 article reviews
    67138s ace2 rabbit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    dpp4 cd26 rabbit  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc dpp4 cd26 rabbit
    a Under normal conditions, (1) terminally differentiated cardiomyocytes have condensed inaccessible chromatin that we hypothesise becomes (2) more accessible by tumour secreted factors, promoting loss of cardiomyocyte maturity and (3) intercalation of DNA damaging chemotherapeutics into now accessible chromatin resulting in DNA breaks and cardiotoxicity (BioRender Lorenzana (2025) https:// BioRender.com/2dyaqis). b Graph shows baseline cumulative inosine and hypoxanthine plasma levels in breast cancer patients from the MANTICORE trial placebo arm. Patients are grouped above or below a threshold of 6 μM: no cardiotoxicity (teal), mild cardiotoxicity (lilac) and moderate cardiotoxicity (purple), n = 22 patients, * P = 0.036 comparing CIC and no CIC above and below a post-hoc analysis determined threshold of 6 μM in a 2 × 2 contingency table, P -value is based on Fisher’s exact two-sided test. c Extracellular purinergic signalling and synthesis of inosine and hypoxanthine (BioRender) . d <t>Immunoblots</t> show <t>CD26,</t> ADA, PNP, CLATHRIN in isolated endosomes in parental and ZNF281 KO A549 cells, n = 3 biological replicates, * P = 0.05 compared to parental endosomes. EEA1 used as a loading control. e Immunoblots show CD26, ADA, PNP in membrane cell fractionation of parental and ZNF281 KO A549 cells, n = 4 biological replicates, * P = 0.0143 compared to parental membrane fraction. EGFR was as a loading control. f Inosine and hypoxanthine measured in cell supernatant, n = 3 biological replicates, * P = 0.05 compared to parental supernatant. g Immunoblots show ZNF281 in control and ZNF281 overexpressing (OE) mouse liver ( n = 4), colon ( n = 3, control and n = 4, ZNF281 OE), ileum ( n = 3, control and n = 4, ZNF281 OE) and stomach ( n = 3) mice, * P = 0.0143, 0.0286, 0.0286, 0.05 respectively compared to control tissue. ACTIN used as a loading control. h Immunoblots show CD26, ADA, PNP in isolated membrane fractions from control and ZNF281 OE liver n = 4 and ileum n = 3 mice, * P = 0.0143 and * P = 0.05 compared to control tissue. EGFR was used as a loading control. i Mouse serum inosine and hypoxanthine in control vs. ZNF281 OE mice, n = 3 control and n = 5 ZNF281 OE mice, * P = 0.0357 compared to control mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values based on one-sided Mann-Whitney Test. Source Data file is provided.
    Dpp4 Cd26 Rabbit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+cd26+rabbit/DPP4%2FCD26+Rabbit+mAb/pmc10104492__pnas__2218083120__sapp-63-12-15
    Average 94 stars, based on 1 article reviews
    dpp4 cd26 rabbit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Scoring of CD26 immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.

    Journal: Frontiers in Oncology

    Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

    doi: 10.3389/fonc.2025.1552587

    Figure Lengend Snippet: Scoring of CD26 immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.

    Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

    Techniques: Immunohistochemistry

    CD26 expression among NSCLC subtypes. Adenocarcinoma expresses significantly more CD26 compared to squamous cell carcinoma (p < 0.0001) and large-cell carcinoma (p = 0.0049). (A) Comparison between adenocarcinoma and adenosquamous carcinoma did not reach statistical significance (p = 0.1104). (B) Comparison of CD26 expression across adenocarcinoma subtypes. Although the overall Kruskal–Wallis test indicated statistical significance (p = 0.0493), none of the pairwise post-hoc comparisons reached significance after correction for multiple testing, suggesting only modest differences among subtypes without robust differences between individual groups. Kruskal–Wallis test, Dunn’s multiple comparisons. **p < 0.01; ****p < 0.0001. NSCLC, non-small cell lung cancer.

    Journal: Frontiers in Oncology

    Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

    doi: 10.3389/fonc.2025.1552587

    Figure Lengend Snippet: CD26 expression among NSCLC subtypes. Adenocarcinoma expresses significantly more CD26 compared to squamous cell carcinoma (p < 0.0001) and large-cell carcinoma (p = 0.0049). (A) Comparison between adenocarcinoma and adenosquamous carcinoma did not reach statistical significance (p = 0.1104). (B) Comparison of CD26 expression across adenocarcinoma subtypes. Although the overall Kruskal–Wallis test indicated statistical significance (p = 0.0493), none of the pairwise post-hoc comparisons reached significance after correction for multiple testing, suggesting only modest differences among subtypes without robust differences between individual groups. Kruskal–Wallis test, Dunn’s multiple comparisons. **p < 0.01; ****p < 0.0001. NSCLC, non-small cell lung cancer.

    Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

    Techniques: Expressing, Comparison

    Survival function of adenocarcinoma patients estimated by Kaplan–Meier method, stratified by immunohistochemical confirmation of CD26/DPP4 expression (CD26-positive vs. CD26-negative). Time is displayed in months. Patients with CD26/DPP4-expressing tumors show a survival benefit compared to their CD26/DPP4-negative counterparts (n = 463, p = 0.0063, log-rank test).

    Journal: Frontiers in Oncology

    Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

    doi: 10.3389/fonc.2025.1552587

    Figure Lengend Snippet: Survival function of adenocarcinoma patients estimated by Kaplan–Meier method, stratified by immunohistochemical confirmation of CD26/DPP4 expression (CD26-positive vs. CD26-negative). Time is displayed in months. Patients with CD26/DPP4-expressing tumors show a survival benefit compared to their CD26/DPP4-negative counterparts (n = 463, p = 0.0063, log-rank test).

    Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

    Techniques: Immunohistochemical staining, Expressing

    EMT marker analysis in adenocarcinoma in correlation with CD26/DPP4 expression, Vimentin, Elastin, β-catenin, Periostin, Versican, and E-cadherin (A–F) . Mann–Whitney U-test; **p < 0.01; ****p < 0.0001. (G–I) Serial section analysis of representative cases; each row represents a single case with various staining scores for specific markers. (G) Upper row: Vimentin score 3/CD26/DPP4 score 3. Lower row: Vimentin score 1/CD26/DPP4 negative. (H) Upper row: Elastin score 3, CD26/DPP4 score 2. Lower row: Elastin score 1, CD26/DPP4 negative. (I) Upper row: E-cadherin score 3, CD26/DPP4 score 1. Lower row: E-cadherin score 1, CD26/DPP4 score 3. Scale bar, 100 µm. EMT, epithelial-to-mesenchymal transition.

    Journal: Frontiers in Oncology

    Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

    doi: 10.3389/fonc.2025.1552587

    Figure Lengend Snippet: EMT marker analysis in adenocarcinoma in correlation with CD26/DPP4 expression, Vimentin, Elastin, β-catenin, Periostin, Versican, and E-cadherin (A–F) . Mann–Whitney U-test; **p < 0.01; ****p < 0.0001. (G–I) Serial section analysis of representative cases; each row represents a single case with various staining scores for specific markers. (G) Upper row: Vimentin score 3/CD26/DPP4 score 3. Lower row: Vimentin score 1/CD26/DPP4 negative. (H) Upper row: Elastin score 3, CD26/DPP4 score 2. Lower row: Elastin score 1, CD26/DPP4 negative. (I) Upper row: E-cadherin score 3, CD26/DPP4 score 1. Lower row: E-cadherin score 1, CD26/DPP4 score 3. Scale bar, 100 µm. EMT, epithelial-to-mesenchymal transition.

    Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

    Techniques: Marker, Expressing, MANN-WHITNEY, Staining

    CD26 inhibition by vildagliptin showed reduced colony formation in a dose-dependent manner in the CD26-expressing mouse lung cancer cell line LLC. (A) Mean ± standard deviation, one-way ANOVA, p = 0.0279, False Discovery Rate (FDR) method by Benjamini–Hochberg. In the CD26-positive human lung cancer cell line H460, we observed a similar trend. (B) Mean ± standard deviation, one-way ANOVA, p = 0.0579. LLC, Lewis lung carcinoma.

    Journal: Frontiers in Oncology

    Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

    doi: 10.3389/fonc.2025.1552587

    Figure Lengend Snippet: CD26 inhibition by vildagliptin showed reduced colony formation in a dose-dependent manner in the CD26-expressing mouse lung cancer cell line LLC. (A) Mean ± standard deviation, one-way ANOVA, p = 0.0279, False Discovery Rate (FDR) method by Benjamini–Hochberg. In the CD26-positive human lung cancer cell line H460, we observed a similar trend. (B) Mean ± standard deviation, one-way ANOVA, p = 0.0579. LLC, Lewis lung carcinoma.

    Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

    Techniques: Inhibition, Expressing, Standard Deviation

    Pharmacological CD26 inhibition reduced the expression of the EMT marker Vimentin in the lung cancer cell lines LLC and H460, tested in 3D culture conditions (A, B) . N-cadherin remained unchanged by vildagliptin treatment (C, D) . Student’s t-test: *p < 0.05. EMT, epithelial-to-mesenchymal transition; LLC, Lewis lung carcinoma.

    Journal: Frontiers in Oncology

    Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

    doi: 10.3389/fonc.2025.1552587

    Figure Lengend Snippet: Pharmacological CD26 inhibition reduced the expression of the EMT marker Vimentin in the lung cancer cell lines LLC and H460, tested in 3D culture conditions (A, B) . N-cadherin remained unchanged by vildagliptin treatment (C, D) . Student’s t-test: *p < 0.05. EMT, epithelial-to-mesenchymal transition; LLC, Lewis lung carcinoma.

    Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

    Techniques: Inhibition, Expressing, Marker

    a Under normal conditions, (1) terminally differentiated cardiomyocytes have condensed inaccessible chromatin that we hypothesise becomes (2) more accessible by tumour secreted factors, promoting loss of cardiomyocyte maturity and (3) intercalation of DNA damaging chemotherapeutics into now accessible chromatin resulting in DNA breaks and cardiotoxicity (BioRender Lorenzana (2025) https:// BioRender.com/2dyaqis). b Graph shows baseline cumulative inosine and hypoxanthine plasma levels in breast cancer patients from the MANTICORE trial placebo arm. Patients are grouped above or below a threshold of 6 μM: no cardiotoxicity (teal), mild cardiotoxicity (lilac) and moderate cardiotoxicity (purple), n = 22 patients, * P = 0.036 comparing CIC and no CIC above and below a post-hoc analysis determined threshold of 6 μM in a 2 × 2 contingency table, P -value is based on Fisher’s exact two-sided test. c Extracellular purinergic signalling and synthesis of inosine and hypoxanthine (BioRender) . d Immunoblots show CD26, ADA, PNP, CLATHRIN in isolated endosomes in parental and ZNF281 KO A549 cells, n = 3 biological replicates, * P = 0.05 compared to parental endosomes. EEA1 used as a loading control. e Immunoblots show CD26, ADA, PNP in membrane cell fractionation of parental and ZNF281 KO A549 cells, n = 4 biological replicates, * P = 0.0143 compared to parental membrane fraction. EGFR was as a loading control. f Inosine and hypoxanthine measured in cell supernatant, n = 3 biological replicates, * P = 0.05 compared to parental supernatant. g Immunoblots show ZNF281 in control and ZNF281 overexpressing (OE) mouse liver ( n = 4), colon ( n = 3, control and n = 4, ZNF281 OE), ileum ( n = 3, control and n = 4, ZNF281 OE) and stomach ( n = 3) mice, * P = 0.0143, 0.0286, 0.0286, 0.05 respectively compared to control tissue. ACTIN used as a loading control. h Immunoblots show CD26, ADA, PNP in isolated membrane fractions from control and ZNF281 OE liver n = 4 and ileum n = 3 mice, * P = 0.0143 and * P = 0.05 compared to control tissue. EGFR was used as a loading control. i Mouse serum inosine and hypoxanthine in control vs. ZNF281 OE mice, n = 3 control and n = 5 ZNF281 OE mice, * P = 0.0357 compared to control mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values based on one-sided Mann-Whitney Test. Source Data file is provided.

    Journal: Nature Communications

    Article Title: Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents

    doi: 10.1038/s41467-025-62172-4

    Figure Lengend Snippet: a Under normal conditions, (1) terminally differentiated cardiomyocytes have condensed inaccessible chromatin that we hypothesise becomes (2) more accessible by tumour secreted factors, promoting loss of cardiomyocyte maturity and (3) intercalation of DNA damaging chemotherapeutics into now accessible chromatin resulting in DNA breaks and cardiotoxicity (BioRender Lorenzana (2025) https:// BioRender.com/2dyaqis). b Graph shows baseline cumulative inosine and hypoxanthine plasma levels in breast cancer patients from the MANTICORE trial placebo arm. Patients are grouped above or below a threshold of 6 μM: no cardiotoxicity (teal), mild cardiotoxicity (lilac) and moderate cardiotoxicity (purple), n = 22 patients, * P = 0.036 comparing CIC and no CIC above and below a post-hoc analysis determined threshold of 6 μM in a 2 × 2 contingency table, P -value is based on Fisher’s exact two-sided test. c Extracellular purinergic signalling and synthesis of inosine and hypoxanthine (BioRender) . d Immunoblots show CD26, ADA, PNP, CLATHRIN in isolated endosomes in parental and ZNF281 KO A549 cells, n = 3 biological replicates, * P = 0.05 compared to parental endosomes. EEA1 used as a loading control. e Immunoblots show CD26, ADA, PNP in membrane cell fractionation of parental and ZNF281 KO A549 cells, n = 4 biological replicates, * P = 0.0143 compared to parental membrane fraction. EGFR was as a loading control. f Inosine and hypoxanthine measured in cell supernatant, n = 3 biological replicates, * P = 0.05 compared to parental supernatant. g Immunoblots show ZNF281 in control and ZNF281 overexpressing (OE) mouse liver ( n = 4), colon ( n = 3, control and n = 4, ZNF281 OE), ileum ( n = 3, control and n = 4, ZNF281 OE) and stomach ( n = 3) mice, * P = 0.0143, 0.0286, 0.0286, 0.05 respectively compared to control tissue. ACTIN used as a loading control. h Immunoblots show CD26, ADA, PNP in isolated membrane fractions from control and ZNF281 OE liver n = 4 and ileum n = 3 mice, * P = 0.0143 and * P = 0.05 compared to control tissue. EGFR was used as a loading control. i Mouse serum inosine and hypoxanthine in control vs. ZNF281 OE mice, n = 3 control and n = 5 ZNF281 OE mice, * P = 0.0357 compared to control mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values based on one-sided Mann-Whitney Test. Source Data file is provided.

    Article Snippet: Antibody dilution was 1:1000 for the following immunoblots CD26 (cell signalling technology 67138), ADA (abcam ab175310), PNP (Novus Biological MAB6486), EGFR (cell signalling technology 2232), EEA1 (Cell signalling technology C45B10), Clathrin (cell signalling technology 4796), ZNF281 (Santa Cruz SC-166933), P-CAMKII (cell signalling technology D21E4), GFP (cell signalling technology D5.1 2956), HAX1 (Proteintech 11266-1-AP), MEIS1 (LS-Bio LS-C148605), HoxB13 (MyBioSource MBS7050847), Runx1 (MyBioSource MBS8500277), Dab2 (cell signalling technology D7O9T), K9 Ac-H3 (cell signalling technology C5B11), S10 P-H3 (cell signalling technology 9701), S33 P-RPA (cell signalling technology E9N1T), Cytochrome C (Santa Cruz sc-8385), b-Tubulin (cell signalling technology 9F3), MFN2 (cell signalling techonology D1E9), Lamin A/C (cell signalling technology 4C11), ATP5A (abcam ab14748), ATP5C (abcam ab180149), CypD (Abcam ab167513), P53 (cell signalling technology 1C12), APAF1 (cell signalling technology D5C3), C-Cas9 (cell signalling technology 5A1E).

    Techniques: Clinical Proteomics, Western Blot, Isolation, Control, Membrane, Cell Fractionation, MANN-WHITNEY

    a Immunoblots show T286 P-CAMKIIδ and RBFOX1 after A 2A agonists treatment, n = 3 biological replicates, * P = 0.05 compared to vehicle. b Immunoblots show GFP, T286 P-CAMKIIδ and RBFOX1 after adenovirus treatment overexpressing GFP or CAMKIIδ, n = 3 biological replicates, * P = 0.05 compared to GFP. c Immunoblots show T286 P-CAMKIIδ and RBFOX1 after A 2A agonist UK-432097 dose-response, n = 3 biological replicates, * P = 0.05 compared to vehicle. d Immunoblots show T286 P- CAMKIIδ and RBFOX1 after CAMKII inhibitor KN93 ± inosine, * P = 0.0143 compared to vehicle, # P = 0.0143 compared to inosine. e Immunoblots show RBFOX1 in A549 cells transfected with empty vector, RBFOX1 WT, T197E RBFOX1 ± caspase 1 inhibitor (YVAD-CMK) or pan-caspase inhibitor (YVAD-CHO), n = 3 biological replicates, * P = 0.05 compared to WT, # P = 0.05 compared to T197E. f Immunoblots show RBFOX1 after UK-432097 ± YVAD-CMK treatment, * P = 0.0286 compared to vehicle, # P = 0.0143 compared to UK-432097. g Boyden chamber with A549 cancer cells plated above cardiomyocytes separated by inlets allowing only metabolite transfer. Immunoblots show RBFOX1 in these cardiomyocytes, n = 3 biological replicates, * P = 0.05 compared to control, # P = 0.05 compared to parental. h Immunoblots show T286 P- CAMKIIδ and RBFOX1 ran on separate gels processed in parallel from non-tumour control, parental and ZNF281 KO A549 tumour mice, n = 4 mice, * P = 0.0143 compared to control, # P = 0.0143 compared to ZNF281 KO. i Cardiac function assessed by echocardiography showing ejection fraction (EF) and fractional shortening (FS). Values expressed as median ± IQR. n = 7 for untreated groups and n = 5 for doxorubicin treated groups ** P = 0.013 compared to untreated parental tumour mice, ^^ P = 0.0040 compared to doxorubicin-treated ZNF281 KO tumour mice, ## P = 0.0013, ## P = 0.0025 compared to untreated ZNF281 KO tumour mice for EF and FS respectively. j Immunoblots show RBFOX1 from inosine injected mice compared to controls. Graph depicts serum inosine+ hypoxanthine serum levels. n = 5 mice for immunoblots, ** P = 0.004 compared to vehicle and n = 3 mice for serum, * P = 0.05 compared to vehicle. Unless otherwise stated, all treatments in isolated mouse cardiomyocytes for 72 h and targets run on the same gel. Quantification values expressed as mean ± SEM, n = 4 biological replicates. P < 0.05 for Kruskal Wallis test if multiple comparisons, P values based on one-sided Mann-Whitney Test. ACTIN used as a loading control for each blot. Source Data file is provided.

    Journal: Nature Communications

    Article Title: Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents

    doi: 10.1038/s41467-025-62172-4

    Figure Lengend Snippet: a Immunoblots show T286 P-CAMKIIδ and RBFOX1 after A 2A agonists treatment, n = 3 biological replicates, * P = 0.05 compared to vehicle. b Immunoblots show GFP, T286 P-CAMKIIδ and RBFOX1 after adenovirus treatment overexpressing GFP or CAMKIIδ, n = 3 biological replicates, * P = 0.05 compared to GFP. c Immunoblots show T286 P-CAMKIIδ and RBFOX1 after A 2A agonist UK-432097 dose-response, n = 3 biological replicates, * P = 0.05 compared to vehicle. d Immunoblots show T286 P- CAMKIIδ and RBFOX1 after CAMKII inhibitor KN93 ± inosine, * P = 0.0143 compared to vehicle, # P = 0.0143 compared to inosine. e Immunoblots show RBFOX1 in A549 cells transfected with empty vector, RBFOX1 WT, T197E RBFOX1 ± caspase 1 inhibitor (YVAD-CMK) or pan-caspase inhibitor (YVAD-CHO), n = 3 biological replicates, * P = 0.05 compared to WT, # P = 0.05 compared to T197E. f Immunoblots show RBFOX1 after UK-432097 ± YVAD-CMK treatment, * P = 0.0286 compared to vehicle, # P = 0.0143 compared to UK-432097. g Boyden chamber with A549 cancer cells plated above cardiomyocytes separated by inlets allowing only metabolite transfer. Immunoblots show RBFOX1 in these cardiomyocytes, n = 3 biological replicates, * P = 0.05 compared to control, # P = 0.05 compared to parental. h Immunoblots show T286 P- CAMKIIδ and RBFOX1 ran on separate gels processed in parallel from non-tumour control, parental and ZNF281 KO A549 tumour mice, n = 4 mice, * P = 0.0143 compared to control, # P = 0.0143 compared to ZNF281 KO. i Cardiac function assessed by echocardiography showing ejection fraction (EF) and fractional shortening (FS). Values expressed as median ± IQR. n = 7 for untreated groups and n = 5 for doxorubicin treated groups ** P = 0.013 compared to untreated parental tumour mice, ^^ P = 0.0040 compared to doxorubicin-treated ZNF281 KO tumour mice, ## P = 0.0013, ## P = 0.0025 compared to untreated ZNF281 KO tumour mice for EF and FS respectively. j Immunoblots show RBFOX1 from inosine injected mice compared to controls. Graph depicts serum inosine+ hypoxanthine serum levels. n = 5 mice for immunoblots, ** P = 0.004 compared to vehicle and n = 3 mice for serum, * P = 0.05 compared to vehicle. Unless otherwise stated, all treatments in isolated mouse cardiomyocytes for 72 h and targets run on the same gel. Quantification values expressed as mean ± SEM, n = 4 biological replicates. P < 0.05 for Kruskal Wallis test if multiple comparisons, P values based on one-sided Mann-Whitney Test. ACTIN used as a loading control for each blot. Source Data file is provided.

    Article Snippet: Antibody dilution was 1:1000 for the following immunoblots CD26 (cell signalling technology 67138), ADA (abcam ab175310), PNP (Novus Biological MAB6486), EGFR (cell signalling technology 2232), EEA1 (Cell signalling technology C45B10), Clathrin (cell signalling technology 4796), ZNF281 (Santa Cruz SC-166933), P-CAMKII (cell signalling technology D21E4), GFP (cell signalling technology D5.1 2956), HAX1 (Proteintech 11266-1-AP), MEIS1 (LS-Bio LS-C148605), HoxB13 (MyBioSource MBS7050847), Runx1 (MyBioSource MBS8500277), Dab2 (cell signalling technology D7O9T), K9 Ac-H3 (cell signalling technology C5B11), S10 P-H3 (cell signalling technology 9701), S33 P-RPA (cell signalling technology E9N1T), Cytochrome C (Santa Cruz sc-8385), b-Tubulin (cell signalling technology 9F3), MFN2 (cell signalling techonology D1E9), Lamin A/C (cell signalling technology 4C11), ATP5A (abcam ab14748), ATP5C (abcam ab180149), CypD (Abcam ab167513), P53 (cell signalling technology 1C12), APAF1 (cell signalling technology D5C3), C-Cas9 (cell signalling technology 5A1E).

    Techniques: Western Blot, Transfection, Plasmid Preparation, Control, Injection, Isolation, MANN-WHITNEY

    a Immunoblots show RBFOX1, MEIS1, HOXB13, RUNX1, DAB2, K9 Ac-H3, S10 P-H3, and S33 P- RPA in control Cre + and RBFOX1 KD Cre + , n = 5 mice, all comparisons ** P = 0.004 except MEIS1, ** P = 0.0079 compared to control Cre + where RBFOX1 and MEIS1, HOXB13, RUNX1, DAB2 and K9 Ac-H3, S10 P-H3, S33 P- RPA are ran on separate gels and processed in parallel. b Immunoblots show RBFOX1, MEIS1, HOXB13, DAB2, and K9 Ac-H3 in adult compared to foetal mouse heart tissue, n = 2 mice where RBFOX1 and MEIS1, HOXB13, DAB2 and K9 Ac-H3 are ran on separate gels and processed in parallel. c mPTP assay measuring calcein AM fluorescence (green) in adult control Cre + and RBFOX1 KD Cre + cardiomyocytes ± cyclosporin A for 30 minutes (CSA, a mPTP inhibitor), n = 3 biological replicates, * P = 0.05 compared to control Cre + , # P = 0.05 compared to RBFOX1 KD Cre + . d Immunoblots show GRB7 in cardiomyocytes isolated from control Cre + and RBFOX1 KD Cre + mice, n = 5 mice, ** P = 0.004 compared to control Cre + . e Immunoblots show RSV GRB7, TUBULIN, MFN2, LAMIN A/C in cellular fractionation in isolated cardiomyocytes, n = 2 mice. f Immunoblots show RBFOX1 and GRB7 in heart and tumour samples depicting RSV GRB7 is distinct from the full-length tumour form, n = 2 mice. g Co-immunoprecipitation of RSV GRB7 and F1-ATP5α shows RSV GRB7, CypD, FO-ATP5c, F1- ATP5α in isolated wildtype cardiomyocytes, n = 3 mice. h Mitochondrial RSV GRB7 sequesters CypD from binding ATP synthase components allowing for efficient ATP production and membrane potential. RSV GRB7 loss now allows CypD binding to ATP synthase components to ‘hijack’ this channel and produce a functional mPTP. i mPTP assay measuring calcein AM (green) in control compared to GRB7-deficient cardiomyocytes ± cyclosporin A for 30 minutes. n = 3 biological replicates, * P = 0.05 compared to control Cre + , # P = 0.05 compared to GRB7 KD Cre + . j Immunoblot shows cytochrome c and TUBULIN in cytosolic fraction of isolated control Cre + and GRB7-deficient cardiomyocytes, n = 2 mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values are based on one-sided Mann-Whitney Test and ACTIN was used as a loading control for each blot. Source Data file is provided.

    Journal: Nature Communications

    Article Title: Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents

    doi: 10.1038/s41467-025-62172-4

    Figure Lengend Snippet: a Immunoblots show RBFOX1, MEIS1, HOXB13, RUNX1, DAB2, K9 Ac-H3, S10 P-H3, and S33 P- RPA in control Cre + and RBFOX1 KD Cre + , n = 5 mice, all comparisons ** P = 0.004 except MEIS1, ** P = 0.0079 compared to control Cre + where RBFOX1 and MEIS1, HOXB13, RUNX1, DAB2 and K9 Ac-H3, S10 P-H3, S33 P- RPA are ran on separate gels and processed in parallel. b Immunoblots show RBFOX1, MEIS1, HOXB13, DAB2, and K9 Ac-H3 in adult compared to foetal mouse heart tissue, n = 2 mice where RBFOX1 and MEIS1, HOXB13, DAB2 and K9 Ac-H3 are ran on separate gels and processed in parallel. c mPTP assay measuring calcein AM fluorescence (green) in adult control Cre + and RBFOX1 KD Cre + cardiomyocytes ± cyclosporin A for 30 minutes (CSA, a mPTP inhibitor), n = 3 biological replicates, * P = 0.05 compared to control Cre + , # P = 0.05 compared to RBFOX1 KD Cre + . d Immunoblots show GRB7 in cardiomyocytes isolated from control Cre + and RBFOX1 KD Cre + mice, n = 5 mice, ** P = 0.004 compared to control Cre + . e Immunoblots show RSV GRB7, TUBULIN, MFN2, LAMIN A/C in cellular fractionation in isolated cardiomyocytes, n = 2 mice. f Immunoblots show RBFOX1 and GRB7 in heart and tumour samples depicting RSV GRB7 is distinct from the full-length tumour form, n = 2 mice. g Co-immunoprecipitation of RSV GRB7 and F1-ATP5α shows RSV GRB7, CypD, FO-ATP5c, F1- ATP5α in isolated wildtype cardiomyocytes, n = 3 mice. h Mitochondrial RSV GRB7 sequesters CypD from binding ATP synthase components allowing for efficient ATP production and membrane potential. RSV GRB7 loss now allows CypD binding to ATP synthase components to ‘hijack’ this channel and produce a functional mPTP. i mPTP assay measuring calcein AM (green) in control compared to GRB7-deficient cardiomyocytes ± cyclosporin A for 30 minutes. n = 3 biological replicates, * P = 0.05 compared to control Cre + , # P = 0.05 compared to GRB7 KD Cre + . j Immunoblot shows cytochrome c and TUBULIN in cytosolic fraction of isolated control Cre + and GRB7-deficient cardiomyocytes, n = 2 mice. Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values are based on one-sided Mann-Whitney Test and ACTIN was used as a loading control for each blot. Source Data file is provided.

    Article Snippet: Antibody dilution was 1:1000 for the following immunoblots CD26 (cell signalling technology 67138), ADA (abcam ab175310), PNP (Novus Biological MAB6486), EGFR (cell signalling technology 2232), EEA1 (Cell signalling technology C45B10), Clathrin (cell signalling technology 4796), ZNF281 (Santa Cruz SC-166933), P-CAMKII (cell signalling technology D21E4), GFP (cell signalling technology D5.1 2956), HAX1 (Proteintech 11266-1-AP), MEIS1 (LS-Bio LS-C148605), HoxB13 (MyBioSource MBS7050847), Runx1 (MyBioSource MBS8500277), Dab2 (cell signalling technology D7O9T), K9 Ac-H3 (cell signalling technology C5B11), S10 P-H3 (cell signalling technology 9701), S33 P-RPA (cell signalling technology E9N1T), Cytochrome C (Santa Cruz sc-8385), b-Tubulin (cell signalling technology 9F3), MFN2 (cell signalling techonology D1E9), Lamin A/C (cell signalling technology 4C11), ATP5A (abcam ab14748), ATP5C (abcam ab180149), CypD (Abcam ab167513), P53 (cell signalling technology 1C12), APAF1 (cell signalling technology D5C3), C-Cas9 (cell signalling technology 5A1E).

    Techniques: Western Blot, Control, Fluorescence, Isolation, Cell Fractionation, Immunoprecipitation, Binding Assay, Membrane, Functional Assay, MANN-WHITNEY

    a Immunoblots show RBFOX1, DAB2, HOXB13, RSV GRB7, K9 Ac-H3, S10 P-H3, and S33 P-RPA from Control and ZNF281 OE, n = 5 mice, * P = 0.0159 for DAB2, * P = 0.0278 for S33 P-RPA and ** P = 0.004 for all others compared to Control where each target is run on a separate gel and processed in parallel except RBFOX1, HOXB13 and S10 P-H3, S33 P-RPA. b Comet assay in control vs. ZNF281 OE or ( c ) control Cre + vs. RBFOX1 KD Cre + cardiomyocytes treated with doxorubicin (1 μM) for 72 h (mean data in Supplementary Fig. ). d Immunoblots show P53, APAF1, cleaved caspase 9 (c-CAS 9) from control and ZNF281 OE or ( e) Control Cre + and RBFOX1 KD Cre + mice after chemotherapies: doxorubicin (1 μM), epirubicin (1 μM), cisplatin (500 nM), etoposide (500 nM), cyclophosphamide (500 nM), n = 3 biological replicates, * P = 0.05 compared to paired Control or control Cre + chemotherapy. f Control and ZNF281 OE or ( g ) Control Cre + and RBFOX1 KD Cre + mice received doxorubicin and cardiac function was assessed via echocardiography using ejection fraction (EF), fractional shortening (FS), cardiac output (CO), systolic LV anterior/posterior wall thickness (LVAW;s, LVPW;s), diastolic LV anterior/posterior wall thickness (LVAW;d, LVPW;d), and end-diastolic volume (LVEDV). Values are expressed as median ± IQR. n = 6 mice for both control and ZNF281 OE * P = 0.0156 compared to baseline Control for all parameters except CO (* P = 0.0312), # P = 0.0156 compared to baseline ZNF281 OE, ^ P = 0.013, ^^ P = 0.0043 compared to DOX ZNF281 OE. n = 12 for control Cre + and n = 13 for RBFOX1 KD Cre + * P = 0.032, *** P = 0.0002 compared to baseline control Cre + , ### P = 0.0001 compared to baseline RBFOX1 KD Cre + , ^ P = 0.0149, ^^^ P = 0.001,^^^^ P < 0.0001 compared to DOX RBFOX1 KD Cre + , P values are based on Mann-Whitney Test. h Immunoblots show RBFOX1, P53, APAF1, c-CAS9 from control Cre + vs. RBFOX1 KD Cre + treated with doxorubicin, n = 10 mice, ** P = 0.004 compared to control Cre + . P97 was used as a loading control. Spearman’s rank order correlation shows RBFOX1 correlates negatively to P53 r = -0.7576, P = 0.0075), APAF1 r = -0 .8424, P = 0.019), and c- CAS9 ( r = -0.7455, P = 0.0087). Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values are based on one-sided Mann-Whitney Test and ACTIN was used as a loading control. Source Data file is provided.

    Journal: Nature Communications

    Article Title: Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents

    doi: 10.1038/s41467-025-62172-4

    Figure Lengend Snippet: a Immunoblots show RBFOX1, DAB2, HOXB13, RSV GRB7, K9 Ac-H3, S10 P-H3, and S33 P-RPA from Control and ZNF281 OE, n = 5 mice, * P = 0.0159 for DAB2, * P = 0.0278 for S33 P-RPA and ** P = 0.004 for all others compared to Control where each target is run on a separate gel and processed in parallel except RBFOX1, HOXB13 and S10 P-H3, S33 P-RPA. b Comet assay in control vs. ZNF281 OE or ( c ) control Cre + vs. RBFOX1 KD Cre + cardiomyocytes treated with doxorubicin (1 μM) for 72 h (mean data in Supplementary Fig. ). d Immunoblots show P53, APAF1, cleaved caspase 9 (c-CAS 9) from control and ZNF281 OE or ( e) Control Cre + and RBFOX1 KD Cre + mice after chemotherapies: doxorubicin (1 μM), epirubicin (1 μM), cisplatin (500 nM), etoposide (500 nM), cyclophosphamide (500 nM), n = 3 biological replicates, * P = 0.05 compared to paired Control or control Cre + chemotherapy. f Control and ZNF281 OE or ( g ) Control Cre + and RBFOX1 KD Cre + mice received doxorubicin and cardiac function was assessed via echocardiography using ejection fraction (EF), fractional shortening (FS), cardiac output (CO), systolic LV anterior/posterior wall thickness (LVAW;s, LVPW;s), diastolic LV anterior/posterior wall thickness (LVAW;d, LVPW;d), and end-diastolic volume (LVEDV). Values are expressed as median ± IQR. n = 6 mice for both control and ZNF281 OE * P = 0.0156 compared to baseline Control for all parameters except CO (* P = 0.0312), # P = 0.0156 compared to baseline ZNF281 OE, ^ P = 0.013, ^^ P = 0.0043 compared to DOX ZNF281 OE. n = 12 for control Cre + and n = 13 for RBFOX1 KD Cre + * P = 0.032, *** P = 0.0002 compared to baseline control Cre + , ### P = 0.0001 compared to baseline RBFOX1 KD Cre + , ^ P = 0.0149, ^^^ P = 0.001,^^^^ P < 0.0001 compared to DOX RBFOX1 KD Cre + , P values are based on Mann-Whitney Test. h Immunoblots show RBFOX1, P53, APAF1, c-CAS9 from control Cre + vs. RBFOX1 KD Cre + treated with doxorubicin, n = 10 mice, ** P = 0.004 compared to control Cre + . P97 was used as a loading control. Spearman’s rank order correlation shows RBFOX1 correlates negatively to P53 r = -0.7576, P = 0.0075), APAF1 r = -0 .8424, P = 0.019), and c- CAS9 ( r = -0.7455, P = 0.0087). Unless otherwise stated, targets are run on the same gel and quantification values are expressed as mean ± SEM, P values are based on one-sided Mann-Whitney Test and ACTIN was used as a loading control. Source Data file is provided.

    Article Snippet: Antibody dilution was 1:1000 for the following immunoblots CD26 (cell signalling technology 67138), ADA (abcam ab175310), PNP (Novus Biological MAB6486), EGFR (cell signalling technology 2232), EEA1 (Cell signalling technology C45B10), Clathrin (cell signalling technology 4796), ZNF281 (Santa Cruz SC-166933), P-CAMKII (cell signalling technology D21E4), GFP (cell signalling technology D5.1 2956), HAX1 (Proteintech 11266-1-AP), MEIS1 (LS-Bio LS-C148605), HoxB13 (MyBioSource MBS7050847), Runx1 (MyBioSource MBS8500277), Dab2 (cell signalling technology D7O9T), K9 Ac-H3 (cell signalling technology C5B11), S10 P-H3 (cell signalling technology 9701), S33 P-RPA (cell signalling technology E9N1T), Cytochrome C (Santa Cruz sc-8385), b-Tubulin (cell signalling technology 9F3), MFN2 (cell signalling techonology D1E9), Lamin A/C (cell signalling technology 4C11), ATP5A (abcam ab14748), ATP5C (abcam ab180149), CypD (Abcam ab167513), P53 (cell signalling technology 1C12), APAF1 (cell signalling technology D5C3), C-Cas9 (cell signalling technology 5A1E).

    Techniques: Western Blot, Control, Single Cell Gel Electrophoresis, MANN-WHITNEY

    a Immunoblots show RBFOX1, P53, APAF1, c-CAS9 in a well characterised cohort of non- failing and AIC human patient explanted heart tissues. b Quantification values are expressed as mean ± SEM, n = 10 and 12 different patients. *** P = 0.0006 for RBFOX1, *** P = 0.0002 for c-CAS9,**** P < 0.0001 for P53 and APAF1 compared to non-failing patients, P values are based on one-sided Mann-Whitney Test. Individual ACTIN was used as a loading control for each target run on different gels and processed in parallel. c Spearman’s rank order correlation shows RBFOX1 correlates to P53 negatively r = -0.8306, P < 0.0001, to APAF1 negatively r = -0 .7628, P < 0.0001, to c-CAS9 negatively r = -0.6623, P = 0.0004. Source Data file is provided.

    Journal: Nature Communications

    Article Title: Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents

    doi: 10.1038/s41467-025-62172-4

    Figure Lengend Snippet: a Immunoblots show RBFOX1, P53, APAF1, c-CAS9 in a well characterised cohort of non- failing and AIC human patient explanted heart tissues. b Quantification values are expressed as mean ± SEM, n = 10 and 12 different patients. *** P = 0.0006 for RBFOX1, *** P = 0.0002 for c-CAS9,**** P < 0.0001 for P53 and APAF1 compared to non-failing patients, P values are based on one-sided Mann-Whitney Test. Individual ACTIN was used as a loading control for each target run on different gels and processed in parallel. c Spearman’s rank order correlation shows RBFOX1 correlates to P53 negatively r = -0.8306, P < 0.0001, to APAF1 negatively r = -0 .7628, P < 0.0001, to c-CAS9 negatively r = -0.6623, P = 0.0004. Source Data file is provided.

    Article Snippet: Antibody dilution was 1:1000 for the following immunoblots CD26 (cell signalling technology 67138), ADA (abcam ab175310), PNP (Novus Biological MAB6486), EGFR (cell signalling technology 2232), EEA1 (Cell signalling technology C45B10), Clathrin (cell signalling technology 4796), ZNF281 (Santa Cruz SC-166933), P-CAMKII (cell signalling technology D21E4), GFP (cell signalling technology D5.1 2956), HAX1 (Proteintech 11266-1-AP), MEIS1 (LS-Bio LS-C148605), HoxB13 (MyBioSource MBS7050847), Runx1 (MyBioSource MBS8500277), Dab2 (cell signalling technology D7O9T), K9 Ac-H3 (cell signalling technology C5B11), S10 P-H3 (cell signalling technology 9701), S33 P-RPA (cell signalling technology E9N1T), Cytochrome C (Santa Cruz sc-8385), b-Tubulin (cell signalling technology 9F3), MFN2 (cell signalling techonology D1E9), Lamin A/C (cell signalling technology 4C11), ATP5A (abcam ab14748), ATP5C (abcam ab180149), CypD (Abcam ab167513), P53 (cell signalling technology 1C12), APAF1 (cell signalling technology D5C3), C-Cas9 (cell signalling technology 5A1E).

    Techniques: Western Blot, MANN-WHITNEY, Control